ライフサイエンスコーパス: type 2 DM

1 l antimicrobials in patients with type 1 and type 2 DM.

2 tion are similar in patients with type 1 and type 2 DM.

3 or function in subjects with both type 1 and type 2 DM.

4 The prevalence of type 1 DM and type 2 DM was compared between patients with incident RA

5 years with hypertension (>130/80 mm Hg) and type 2 DM (glycosylated hemoglobin [HbA1c], 6.5%-8.5%) a

6 s (peanuts, soybeans, and other legumes) and type 2 DM incidence.

7 In obesity and type 2 DM, there is an increased content of lipid within

8 and to the pathogenesis of both obesity and type 2 DM.

9 pect of IR of skeletal muscle in obesity and type 2 DM.

10 luded proximal myotonic myopathy (PROMM) and type 2 DM (DM2) but without the DM1 mutation, showed lin

11 No association between RA and type 2 DM was observed.

12 We induced type 1 (T1D) and type 2 DM (T2D) in a portfolio of genetic mouse models c

13 rvival in patients with type 1 DM (T1DM) and type 2 DM (T2DM) following CABG.

14 and in combination, which was designated as "type 2 DM phenotype" (n=5).

15 There is a modest association between type 2 DM and CRC among men, but not women.

16 When we allowed for interaction between type 2 DM and other key risk factors, DM remained a sign

17 nhibitor, is regulated in skeletal muscle by type 2 DM and ischemia.

18 p and 402 men in the placebo group developed type 2 DM (relative risk, 0.98; 95% confidence interval,

19 significantly increased risk for developing type 2 DM that is not completely explained by obesity.

20 hus have a 10% annualized risk of developing type 2 DM.

21 were included (199 for type 1 DM and 144 for type 2 DM, and 38 from other sources) if they involved h

22 insulin resistance is the major etiology for type 2 DM and numerous evidences showed that HCV infecti

23 esistance, characterized by risk factors for type 2 DM, can predict islet graft survival in type 1 DM

24 Risk factors for type 2 DM, such as positive family history of type 2 DM

25 Predisposition for type 2 DM can coexist with the type 1 DM phenotype and i

26 rength was associated with a 3-fold risk for type 2 DM (adjusted hazard ratio, 3.07 [CI, 2.88 to 3.27

27 associated with increased long-term risk for type 2 DM, even among those with normal body mass index.

28 pendently associated with increased risk for type 2 DM.

29 Of these patients, 1731 (27.9%) had type 2 DM.

30 risk of incident CRC compared to not having type 2 DM (RR: 1.24; 95% CI: 1.08-1.44); risk was higher

31 ith LV systolic and diastolic dysfunction in type 2 DM; this may explain in part the relationship of

32 sedentary lifestyle and a marked increase in type 2 DM among children.

33 review recent findings that indicate that in type 2 DM and obesity, skeletal muscle manifests inflexi

34 moderate streptozotocin injection to induce type 2 DM.

35 However, data linking type 2 DM risk and legume intake are limited.

36 the prevention of type 2 diabetes mellitus (type 2 DM).

37 (CP) patients with type-2 diabetes mellitus (type-2 DM) than controls (systemically healthy individua

38 Among men, type 2 DM was associated with increased risk of incident

39 ed type 1 DM (DM1) and transgenic Lep(ob/ob) type 2 DM (DM2) diabetic murine models as donors and non

40 Thirty-three percent of type 1 and 48% of type 2 DM patients had significant stenosis (> or = 70%)

41 We investigated associations of type 2 DM and insulin use with CRC risk.

42 -years of follow-up, there were 507 cases of type 2 DM.

43 Improved glycemic control of type 2 DM is associated with substantial short-term symp

44 aboratory data, as well as family history of type 2 DM (first degree relatives), were collected from

45 ype 2 DM, such as positive family history of type 2 DM (n=11) and overweight (body mass index >25 kg/

46 Neither positive family history of type 2 DM nor overweight at baseline could predict islet

47 We followed 64,227 women with no history of type 2 DM, cancer, or cardiovascular disease at study re

48 solute difference in cumulative incidence of type 2 DM between the lowest and highest tertiles of bot

49 Incidence of type 2 DM did not differ between groups: 396 men in the

50 ta-carotene supplementation and incidence of type 2 DM persisted despite multivariate adjustment.

51 the involvement of E2 in the pathogenesis of type 2 DM and underlying mechanisms were investigated in

52 otein indeed involved in the pathogenesis of type 2 DM by inducing insulin resistance.

53 The multivariate-adjusted relative risk of type 2 DM for the upper quintile compared with the lower

54 rm exposure to air pollution and the risk of type 2 DM.

55 The RR of type 2 DM associated with long or highly irregular menst

56 ge 18 to 22 years, the relative risk (RR) of type 2 DM among women with a menstrual cycle length that

57 The mean duration of type-2 DM among individuals in group-1 was 8.2 years (7

58 volving insulin use in adults with type 1 or type 2 DM from January 1, 1980, to January 8, 2003.

59 in 120 outpatients (240 eyes) with type 1 or type 2 DM.

60 eyes from 24 individuals with prediabetes or type 2 DM (glycated hemoglobin [HbA1c] >= 5.7) and 16 co

61 Overall, type 2 DM is still relatively infrequent; however, the h

62 Overall, type 2 DM was still relatively infrequent, but the highe

63 e and soy food consumption and self-reported type 2 DM.

64 ular, was inversely associated with the risk type 2 DM.

65 ears had no effect on the risk of subsequent type 2 DM.

66 Approaches to screening renal disease in the type 2 DM population should incorporate assessment of GF

67 r, when both risk factors were grouped, the "type 2 DM phenotype" was associated with earlier islet g

68 , respectively) were examined in relation to type 2 DM identified from outpatient and inpatient diagn

69 ntensity exercise is normal in uncomplicated type 2 DM but is impaired in those with microvascular co

70 227 with type 2 DM) and 1242 women (108 with type 2 DM) were diagnosed with colon or rectal cancer by

71 rs; mean body mass index, 32 [SD, 5.1]) with type 2 DM (mean duration, 7.7 [SD, 7.2] years; mean glyc

72 he final analytic cohort; 1567 men (227 with type 2 DM) and 1242 women (108 with type 2 DM) were diag

73 periodontitis (118 normoglycemic and 89 with type 2 DM) were analyzed.

74 verall, 13% (sampled n = 171) of adults with type 2 DM (n = 1197) had CRI with a population estimate

75 The population estimate of adults with type 2 DM and CRI in the absence of diabetic retinopathy

76 e both absent in 30% (n = 51) of adults with type 2 DM and CRI.

77 Among older adults with type 2 DM, femoral neck BMD T score and FRAX score were

78 34 008 men were diagnosed with type 2 DM in 39.4 million person-years of follow-up.

79 th GDM and GTD as well as in her father with type 2 DM but was absent in control patients.

80 opic changes to ensure that individuals with type 2 DM and CRI not due to diabetic glomerulosclerosis

81 filtration rate (GFR) among individuals with type 2 DM may not always be due to classic diabetic glom

82 l periodontal treatment of participants with type 2 DM and moderate to severe periodontal disease imp

83 Sixty participants with type 2 DM and moderate to severe periodontal disease wer

84 6; 95% CI: 1.05-1.78), and participants with type 2 DM not using insulin (RR: 1.22, 95% CI: 1.04-1.45

85 1.44); risk was higher for participants with type 2 DM using insulin (RR: 1.36; 95% CI: 1.05-1.78), a

86 d hemoglobin (HbA1c) levels of patients with type 2 DM (DMt2).

87 araoxon in serum samples of 87 patients with type 2 DM and 46 patients with pre-DM showing impaired f

88 In patients with type 2 DM and CP, local delivery of 1% ALN into periodon

89 at 2 years was assessed in 187 patients with type 2 DM and stable coronary artery disease on maintena

90 external validation cohort of patients with type 2 DM but not in an external validation cohort of pa

91 ntrolled, multicenter trial in patients with type 2 DM conducted at 28 clinical sites in the multirac

92 Patients with type 2 DM have a less dysbiotic subgingival microbial pr

93 PON-1 status in patients with type 2 DM may contribute to this association.

94 The shallow and deep sites of patients with type 2 DM presented higher proportions of Actinomyces sp

95 Patients with type 2 DM undergoing bioprosthetic valve implantation ar

96 ithm successfully matched 1113 patients with type 2 DM with the same number of no-DM patients.

97 consent from the patients, 37 patients with type 2 DM without overt heart disease and 23 age-matched

98 In patients with type 2 DM, adding bedtime neutral protamine Hagedorn (is

99 n 18-month treatment period in patients with type 2 DM, pioglitazone slowed progression of CIMT compa

100 ing and softening of the PF in patients with type 2 DM, supporting the hypo-thesis that diabetes-indu

101 roteinase (MMP)-2 and MMP-9 on patients with type 2 DM.

102 egimen that is well suited for patients with type 2 DM.

103 logic regimens for the at-risk patients with type 2 DM.

104 substantial burden of CRI among persons with type 2 DM in the United States is likely due to renal pa

105 ived from soy beans and their products) with type 2 DM was not significant.

106 Group-1: Patients with type-2 DM and CP; group-2: Non-diabetic individuals with

107 evels of AGEs are higher in CP patients with type-2 DM compared to systemically healthy individuals w

108 rsus 2.9% (n=33) in patients with or without type 2 DM (P<0.001), respectively.

109 m with bleeding) of patients with or without type 2 DM were evaluated for levels/proportions of 40 ba

110 s in the GCF of CP patients with and without type-2 DM.

111 Among women, type 2 DM and insulin use were not associated with risk